NEW YORK and MELBOURNE, Australia, March 13, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; Nasdaq: MESO)
today announced it will be featured at two investor conferences in March:
- Oppenheimer 29th Annual Healthcare Conference in New York on Wednesday, March 20, 2019 at 1:00 p.m. ET.
- The Alliance for Regenerative Medicine’s Seventh Annual Cell & Gene Therapy Investor Day in New York on Thursday, March 21,
2019 at 4:15 p.m. ET.
About Mesoblast
Mesoblast Limited (ASX: MSB; Nasdaq: MESO) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The
Company has leveraged its proprietary technology platform to establish a broad portfolio of late-stage product candidates with
three product candidates in Phase 3 trials – acute graft versus host disease, chronic heart failure, and chronic low back pain due
to degenerative disc disease. Through a proprietary process, Mesoblast selects rare mesenchymal lineage precursor and stem cells
from the bone marrow of healthy adults and creates master cell banks, which can be industrially expanded to produce thousands of
doses from each donor that meet stringent release criteria, have lot to lot consistency, and can be used off-the-shelf without the
need for tissue matching. Mesoblast has facilities in Melbourne, New York, Singapore and Texas and is listed on the Australian
Securities Exchange (MSB) and Nasdaq (MESO). www.mesoblast.com
For further information, please contact:
